STRATEC SE : FY review – Sequential improvement, but guidance looks weak
>Top line with positive momentum, but below expectations - Stratec’s Q4 2023 revenues of € 74.2m (+10.8% y-o-y) profited from +12.9% growth in constant currencies), which were 4%/3% below our and the consensus’ expectations. The consolidation of Natech Plastics contributed around 500bp to revenues growth. We like that the company has returned to organic growth in the last quarter, albeit less pronounced than anticipated.Bottom line with sequential growth ...STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.